



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/570,909	03/29/2006	Carsten Hopf	50125/147001	1220

21559 7590 11/20/2009
CLARK & ELBING LLP
101 FEDERAL STREET
BOSTON, MA 02110

EXAMINER

HILL, KEVIN KAI

ART UNIT	PAPER NUMBER
----------	--------------

1633

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

11/20/2009

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentadministrator@clarkelbing.com

Continuation of Substance of Interview including description of the general nature of what was discussed: The breadth of "modulating" embraces compounds that activate gamma secretase activity to reduce Abeta-42 formation; however, the specification only supports decreased FADS2 activity that consequently inhibits γ -secretase activity and thereby achieving a reduction in the production of Abeta-42. While Czirr et al (2008) teach the use of compounds affecting γ -secretase activity to reduce the production of Abeta-42 peptides, Czirr et al do not teach the compounds to stimulate or increase γ -secretase activity to achieve the reduced production of Abeta-42. To advance prosecution, the Examiner proposed cancellation of the claims drawn to "modulating". The Examiner proposed adding the phrase "enzymatically active" before "fatty acid delta-6 desaturase" to clarify that the FADS2 has biological activity, and thus the claims, e.g. Claim 76, do not read upon enzymatically inactive fragments.

In a telephone conversation with Applicant's representative on November 17, 2009, Applicant's representative requested the Examiner refrain from acting on the next Office Action until December 1, 2009 so as to allow Applicant, who is/are foreign inventors, time to respond to the proposed amendments. The Examiner has agreed to do so, and expects a response from Applicant by December 1, 2009. Applicant's representative also requested whether the phrase "functionally active" may be used instead of "enzymatically active", as per [0015, 0018 and 0020] of the published application. Upon review of the definitions provided in the specification, e.g. functionally active includes enzymatically active [0018], the Examiner agrees that the phrase "functionally active" is a sufficient replacement of "enzymatically active".